Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue

Hypertension

Volumn 34, Issue 2, 1999, Pages 171-175

  Campbell, Duncan J ^a   Duncan, Ann Maree ^b   Kladis, Athena ^b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NONE

Author keywords

Angiotensin; Angiotensin converting enzyme; Bradykinin; Heart; Kallidin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; BRADYKININ; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; KALLIDIN; LISINOPRIL; RAMIPRIL; TRANDOLAPRIL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HEART ATRIUM MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; MALE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0032858142     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.2.171     Document Type: Article

References (30)

1. Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K, Johnson WH, Feldman MD. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation. 1994;89:2616-2625.
2. Foult JM, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation. 1988;77:337-344.
3. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GAJ, Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25: 250-259.
4. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P. Effect of early-onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension. 1992;20:478-482.
5. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
6. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
7. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens. 1990;8:715-724.
8. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Raynolds MV, Bristow MR, Perryman MB. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;96:1490-1498.
9. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
10. Kato H, Enjyoji K. Hydroxylated kininogens and kinins. In: Fritz H, Müller-Esterl W, Jochum M, Roscher A, Luppertz K, eds. Recent Progress on Kinins: Biochemistry and Molecular Biology of the Kallikrein-Kinin System. Basel, Switzerland: Birkhäuser Verlag; 1992: 217-224.
11. Campbell DJ, Lawrence AC, Kladis A, Duncan A-M. Strategies for measurement of angiotensin and bradykinin peptides and their metabolites in central nervous system and other tissues. In: Smith AI, ed. Methods in Neurosciences, volume 23: Peptidases and Neuropeptide Processing. Orlando, Fla: Academic Press; 1995:328-343.
12. Campbell DJ, Kladis A, Duncan A-M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993;21:155-165.
13. Campbell DJ, Kladis A, Duncan A-M. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension. 1993;22:513-522.
14. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994; 23:439-449.
15. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues: quantitative analysis by the polymerase chain reaction. J Clin Invest. 1993;91:2058-2064.
16. Danser AH, Van Kesteren CA, Bax WA, Tavenier M, Derkx FH, Saxena PR, Schalekamp MA. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226.
17. Zhuo JL, Froomes P, Casley D, Liu JJ, Murone C, Chai SY, Buxton B, Mendelsohn FAO. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation. 1997;96:174-182.
18. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension. 1998;32:514-520.
19. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein-kinin system is present in rat hearts. Hypertension. 1994;23: 919-923.
20. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
21. Bönner G. Do kinins play a significant role in the antihypertensive and cardioprotective effects of angiotensin I-converting enzyme inhibitors? In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press, Ltd; 1995: 2877-2893.
22. Shimamoto K, Nakagawa M, Iimura O. In vivo concentrations of kinins and angiotensins. Horm Metab Res Suppl. 1990;22:75-79.
23. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Colch). 1994;87:567-574.
24. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995;92:3424-3430.
25. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
26. 2 receptor activation in human heart. J Am Coll Cardiol. 1997;29:1599-1606.
27. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II): studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
28. Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 1995;26:230-235.
29. Rosenbaum C, Cardozo C, Lesser M. Degradation of lysylbradykinin by endopeptidase 24.11 and endopeptidase 24.15. Peptides. 1995;16: 523-525.
30. Ersahin C, Simmons WH. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol. 1997;30:96-101.